|
|
|
A BILL TO BE ENTITLED
|
|
AN ACT
|
|
relating to a study evaluating the use of alternative therapies for |
|
treating certain mental health and other medical conditions. |
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
SECTION 1. (a) In this Act, "department" means the |
|
Department of State Health Services. |
|
(b) The department, in collaboration with the Texas Medical |
|
Board, shall conduct a study to evaluate the therapeutic efficacy |
|
of alternative therapies, including the use of |
|
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and |
|
ketamine, in the treatment of mental health and other medical |
|
conditions, including: |
|
(1) depression; |
|
(2) anxiety; |
|
(3) post-traumatic stress disorder; |
|
(4) bipolar disorder; |
|
(5) chronic pain; and |
|
(6) migraines. |
|
(c) In conducting the study described by Subsection (b) of |
|
this section, the department shall: |
|
(1) evaluate and determine whether alternative |
|
therapies are effective in treating the mental health and other |
|
medical conditions described by that subsection; and |
|
(2) compare the efficacy of the alternative therapies |
|
with the efficacy of treatments currently used for the mental |
|
health and other medical conditions described by that subsection. |
|
(d) Not later than December 1, 2022, the department shall |
|
prepare and submit to the governor, the lieutenant governor, the |
|
speaker of the house of representatives, and each member of the |
|
legislature a written report containing the results of the study |
|
conducted under this section and any recommendations for |
|
legislative or other action. |
|
(e) This Act expires September 1, 2023. |
|
SECTION 2. This Act takes effect immediately if it receives |
|
a vote of two-thirds of all the members elected to each house, as |
|
provided by Section 39, Article III, Texas Constitution. If this |
|
Act does not receive the vote necessary for immediate effect, this |
|
Act takes effect September 1, 2021. |